Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-DNMT3b
- Development stage
- Preclinical
- Lead developer
- Augusta University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
shRNA-DNMT3b is a short hairpin RNA (shRNA) designed to target and silence the expression of DNA methyltransferase 3b (DNMT3b). In MYC-driven malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and Burkitt's lymphoma (BL), the MYC oncogene directly upregulates DNMT3b, which in turn maintains aberrant DNA methylation patterns at CpG islands near gene promoters. This epigenetic regulation leads to the silencing of genes involved in differentiation and apoptosis while promoting tumor cell proliferation. By utilizing RNA interference to knock down DNMT3b levels, shRNA-DNMT3b disrupts these tumor-maintenance programs, leading to the upregulation of genes responsible for differentiation and development and the downregulation of those controlling proliferation and survival. It is primarily used as a research tool to validate DNMT3b as a therapeutic target in MYC-dependent cancers.
- Other names
- short hairpin RNA targeting DNMT3b
02
Targets
DNMT3B (DNA (cytosine-5)-methyltransferase 3B)
Beyond the preview
Go deeper on shRNA-DNMT3b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shRNA-DNMT3b.